PREDICTORS OF MORTALITY AMONG HIV PATIENTS ON ANTIRETROVIRAL TREATMENT IN DR. SARDJITO HOSPITAL YOGYAKARTA

Yurniati 1, Subronto YW 1, Rintiswati N 1, Yuliani FS 1, Watchirs Smith L2, Mathers BM2.
1Center for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia.
2Kirby Institute, Faculty of Medicine, University of New South Wales, Sydney, Australia.

INTRODUCTION

HIV and AIDS are leading causes of death globally [1]. Although antiretroviral therapy (ART) has been widely used in Indonesia, particularly in Yogyakarta the mortality of patients is still high. Previous studies in many countries have shown great variation in mortality levels and factors related to mortality among patients on ART [2,3,4,5].

OBJECTIVES

The aim of this study was to determine the level of mortality and identify its predictors among HIV patients on ART in Dr. Sardjito hospital, Yogyakarta.

METHODS

This retrospective cohort study was conducted among patients who initiated ART between January 2008 to December 2012 in Dr. Sardjito hospital. Patients were followed up for 2 years. Date of age, sex, education level, WHO stage, CD4 counts, hemoglobin level, TB co-infection, cotrimoxazole prophylaxis therapy (CPT), and place of residence were extracted from the ART register, medical records and where necessary through information from peer group.

ELIGIBILITY CRITERIA

Only First visit ≥ 34

Patients had follow-up = 543

Patients include in the analysis n = 524

Pregnant women = 19

SURVIVAL ANALYSIS

At baseline, approximately three quarters of patients were under 40 years of age (75.76%) and the majority of patients had a high level of education (64.12%). The majority of patients were male (86.03%).

A total of 86 (16.41%) patients were found to have died within the 2 year observation period after ART initiation, giving a mortality rate of 12.6 per 100 person-years. The highest mortality rate was observed at three months after ART initiation (41.6 per 100 person-years). The mortality rate decreased over the longer patients undergoing ARV. This mortality rate was higher than study in Ethiopia in 2 years (7/100 per 100 person-years) [6].

In the multivariate analysis, patients with a recorded WHO stage III or IV were at a higher risk of mortality (HR 1.88; 95% CI 1.04 – 3.39) with mortality rate of 8.8 per 100 person-years. Patients with TB co-infection when starting ART were two times more likely to die than those without TB (HR 2.31; 95% CI 1.41 – 3.79) with mortality rate of 7.9 per 100 person-years. Patients who had a CD4 count of less than 200 cell/mm² at baseline were four times more likely to die than patients with a CD4 count above 200 cell/mm² (HR 3.72; 95% CI 1.43 – 9.50) with mortality rate of 4.8 per 100 person-years.

CONCLUSION

The mortality of adult patients with in 2 years of ART initiation was high. Consistent with other studies in Africa and Ethiopia we found WHO stage III and IV [2], TB co-infection [3], CD4 count less than 200 cells/mm² [4], hemoglobin level less than 11 gridl [5] predicted mortality. Age, sex, education level and CPT were found to be associated with mortality in other studies, however we did not find any association with these variables and mortality in our study. Clinical presentations significantly affect the outcomes of patients commencing treatment. Early diagnosis and ART initiation are important to reduce mortality among patients on ART. So counseling and monitoring of patients for early presentation testing for HIV and ART initiation are recommended.

ACKNOWLEDGEMENT

This research project has been funded under the Australian Aid, Regional HIV Capacity Building Program. The views expressed in this publication do not necessarily represent the position of the Australian Government. We would like to thank mentors from Kirby Institute, Faculty of Medicine, University of New South Wales and Center for Tropical Medicine, Faculty of Medicine, Universitas Gadjah Mada, Sardjito Hospital and peer support group Victory Plus.

REFERENCE